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ABSTR ACT: Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment 
is  no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Therefore, it is imperative that early-stage biomarkers are 
identified to enhance the early detection of ovarian cancer. Cancer-testis antigens (CTAs), such as Per ARNT SIM (PAS) domain containing 1 (PASD1), 
are unique in that their expression is restricted to immunologically restricted sites, such as the testis and placenta, which do not express MHC class I, and 
cancer, making them ideally positioned to act as targets for immunotherapy as well as potential biomarkers for cancer detection where expressed. We exam-
ined the expression of PASD1a and b in a number of cell lines, as well as eight healthy ovary samples, eight normal adjacent ovarian tissues, and 191 ovarian 
cancer tissues, which were predominantly stage I (n = 164) and stage II (n = 14) disease. We found that despite the positive staining of skin cancer, only 
one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels. This may reflect the predominantly stage I ovarian cancer samples 
examined. To examine the restriction of PASD1 expression, we examined endometrial tissue arrays and found no expression in 30 malignant tumor tissues, 
23 cases of hyperplasia, or 16 normal endometrial tissues. Our study suggests that the search for a single cancer-testes antigen/biomarker that can detect 
early ovarian cancer must continue.
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Introduction
Ovarian cancer is mainly found in women aged over 50 years, 
although it can occur at any age. Around 225,500 women 
worldwide are diagnosed with ovarian cancer every year, and 
there are about 140,200 associated deaths.1 There are dif-
ferent types of ovarian cancers classified by the type of cell 
from which the cancer originates, including epithelial, germ 
cell, and stromal ovarian cancers, with epithelial ovarian 
cancer (EOC) being the most common type. Ovarian can-
cer is mostly diagnosed in the late stages of the disease, at 
which time, treatment is not as effective, and the cancer may 
have spread beyond the ovaries. However, if ovarian cancer 
is diagnosed in the early stages of the disease, there is a 90% 
survival rate.2 Currently, the marker carbohydrate antigen 
125 (CA125) is used to confirm a diagnosis of ovarian cancer; 
however, CA125 is found most frequently in most stage III 
and stage IV tumors and/or serous tumors. These tumors are 
likely to develop from serous tubal intraepithelial carcinoma 
precursor lesions in the fallopian tubes,3,4 which then coat 
the ovary and fall into the abdominal cavity, and as such, are 
unlikely to be found at stage I of the disease. In contrast, 
clear cell/endometroid tumors arise in the ovary5 and can be 
detected in the early stages of the disease,6 although this is 
still rare.7 Recently, a combination of serum CA125, serum 
HE4, and age was used to triage women with suspected 
ovarian cancer and was found to have a clinically relevant 
sensitivity for discriminating benign from malignant ovarian 
disease.8
Cancer-testis antigens (CTAs) provide attractive tar-
gets in the pursuit of effective cancer immunotherapy. Their 
unique properties of only being expressed in cancer cells and 
not in healthy tissues, apart from immune-privileged sites 
such as the testis,9 means that they have the potential to also 
act as sensitive biomarkers for cancer. Per ARNT SIM (PAS) 
domain containing 1 (PASD1) was identified in diffuse large 
B-cell lymphoma10 and acute myeloid leukemia11 using the 
serological identification of antigens by recombinant expres-
sion cloning also known as the SEREX technique.12 PASD1 
expression was subsequently described in multiple myeloma.13 
PASD1 shows most similarity to the CLOCK gene in mice 
and was recently found to have a role in blocking circadian 
rhythms in human cancer cells.14
Journal name: Biomarkers in Cancer
Journal type: Original Research
Year: 2015
Volume: 7
Running head verso: Khan et al
Running head recto: PASD1 expression in ovarian cancer
Khan et al
32 Biomarkers in CanCer 2015:7
However, few CTAs have been identified as being fre-
quently expressed in ovarian cancer (Table 1) and few investi-
gations have examined PASD1 expression in solid tumors.10,15 
We had hoped to find a new biomarker for early-stage ovarian 
cancer, and to do this, we examined PASD1 protein expres-
sion in ovarian cancer, and endometrial tissue arrays (to show 
specificity of the expression), through immunolabeling.
Materials and Methods
Cell lines and their preparation for immunolabeling. 
Cells were grown in RPMI 1640 media (Sigma) containing 
10% foetal bovine serum (Thermo Fisher) and 1% penicillin 
and streptomycin (Thermo Fisher), in a humidified incuba-
tor at 37°C, and in 5% CO2. Cells were harvested, counted, 
and diluted in PBS (Fisher) to 5 × 106 per mL. Cells were 
recentrifuged for eight minutes at 1200 × g. Supernatant was 
removed, and the cell pellet was resuspended in 1 mL PBS. 
Glass slides (Fisher Scientific) were used, and 10 μL of cell 
solution was spotted on each microscope slide. The slides were 
air dried for at least four hours, double wrapped in Saran 
wrap, and stored at -20°C.
Tissue microarrays (TMAs). The ovarian TMAs 
(OV2084 Biomax) constitute high-density ovary carcinoma 
and adjacent normal ovary tissue sections, including 165 stage 
I, 14 stage II, five stage III, and four stage IV ovary cancer 
samples, as well as eight adjacent normal tissues and eight nor-
mal tissues, single core per case. Ovarian cancer TMAs were 
tested in duplicate for the expression of each antigen and to 
test the controls. The endometrium carcinoma TMA (UT801 
Biomax) incorporated 30 cases of endometrial adenocarci-
noma, 23 of endometrial hyperplasia, six of metastastic dis-
ease, five of endometrial inflammation, 10 adjacent normal 
tissues, and six normal tissues of the uterus, single core per 
case. The endometrium carcinoma tissue array was only tested 
once, and we only examined PASD1b, and not PASD1a, 
expression.
Antibodies. Immunolabeling for each of the antigens was 
performed using antihuman primary antibodies; the mono-
clonal antibody PASD1-1 that recognizes the region common 
to the PASD1a and PASD1b proteins (clone 2ALCC136) 
between aa 195–474 and PASD1-2 (clone 2ALCC128), a 
monoclonal antibody that is specific for aa 540–773 present 
only in the longer PASD1b protein.10,16 CA125 clone OC125 
(90  μg/mL, AbD Serotec), the current industry standard 
used to confirm a diagnosis for ovarian cancer, was used for 
comparison.
Dewaxing of tumour microarrays (TMAs) prior to 
immunolabeling. All TMAs were obtained from US Biomax, 
Inc. TMAs were de waxed in citroclear (TCS Biosciences) 
twice for five minutes, placed in 100% ethanol twice for five 
minutes, and then once in 50% ethanol for five minutes. The 
arrays were washed with tap water, and antigen retrieval was 
performed in Tris/EDTA buffer pH9 (Sigma) in a microwave 
(850 W) for 11 minutes at full power. Following cooling, the 
arrays were washed in TBS. Peroxide block (Dako) was added 
for five minutes, the tissue arrays were washed again in TBS, 
and the excess TBS was carefully removed from the periphery 
of the buttons using absorbent tissues.
Defrosting of frozen cell lines spotted onto glass slides 
prior to immunolabeling. Slides of frozen cells that had been 
spotted onto glass slides were taken from storage at -20°C and 
defrosted for 20 minutes at room temperature before remov-
ing the Saran wrap. A diamond pen (Fisher) was used to mark 
around the area of the slide to be stained (the “button”). The 
cells were fixed by inserting the slides into a Coplin jar contain-
ing 100% 50 mL cold methanol (Fisher) on ice for 15 minutes. 
The slides were removed from the fixative and placed hori-
zontally into a moisture chamber face up. They were washed 
three times in TBS (Sigma), and the excess TBS was carefully 
removed from the periphery of each of the buttons using tissues.
Immunolabeling antigens in cell lines and TMAs. 
A peroxidase block from the Envision Kit (Dako) was added 
to the cells for five minutes. The appropriate primary antibod-
ies were diluted in TBS, and 40 μL of the antibody solution 
added to each button of cells. Actin staining was used as a 
positive control to demonstrate that the assay and its compo-
nent reagents were working. The slides were incubated with 
primary antibody for one hour at room temperature, and then 
washed three times with TBS. The secondary antibody was 
supplied as part of the Envision+ System HRP (DAB) kit 
(Dako) and was a HRP conjugated anti-mouse IgG antibody 
which was added and incubated for 30 minutes at room tem-
perature. Following washes with TBS, 20–30  μL of DAB 
substrate from the Envision kit was added to each cell but-
ton, incubated for five minutes, and then washed gently with 
water. A total of 40 μL of 1:5 dilution Mayer’s hematoxylin: 
Lillie’s Modification (Dako) was added to each button as a 
counterstain and washed with copious amounts of tap water 
to remove all excess stain. Slides were mounted in Faramount 
Aqueous Mounting Medium (Dako) and imaged using the 
virtual microscopy system Olympus Dotslide at 40× magnifi-
cation at the University of Southampton. Samples were scored 
depending on the intensity of the labeling with 0 and 1 being 
classed as negative and 2, 3, and 4 considered as positive.
Statistical analysis. A one-tailed t-test analysis was 
undertaken to compare the distribution of the scoring across 
the different tissue subtypes; in addition, chi2 tests were per-
formed on subgroups of tissues, including those from different 
stages of ovarian cancer and healthy donors.
Results
PASD1 protein expression in cancer cell lines. Although 
the expression of PASD1 protein was detected by immunolabeling 
chronic myeloid leukemia, K562,17 multiple myeloma, THIEL 
(a gift from Prof. Diehl, University of Cologne, Germany), cervi-
cal cancer HeLa,18 colorectal cancer, SW480,19 and melanoma 
Sk-Mel-2820 cell line, PASD1 was not detected in the ovarian 
cancer cell lines: Skov3,21 Ovcar3,22 and A278023 (Fig. 1).16
PASD1 expression in ovarian cancer 
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PASD1 protein expression in normal and normal adja-
cent tissues. The PASD1-1 antibody that immunolabeled 
PASD1a and b scored only 0 in normal adjacent ovarian tis-
sue (NAT) and 0–1 in healthy ovarian tissue, whereas the 
PASD1-2 monoclonal antibody that immunolabels PASD1b 
had immunolabeling scores ranging 0–1 for healthy tissue and 
0–2 for normal adjacent tissue (Table 2A and Fig. 2). Immuno-
labeling of normal endometrial tissue with the anti-PASD1b 
antibody was not observed (Table 2C), although CA125 was 
found to immunolabel some normal endometrial tissues.
PASD1 protein expression in ovarian cancer tissues 
and endometrial arrays. We found no significant expression 
of PASD1a or b in ovarian cancer tissue samples (Fig. 2 and 
Table 2A & B). A comparison of I vs II/III/IV was not signif-
icant for PASD1a + b (P = 0.564) or PASD1b (P = 0.492) Both 
of the PASD1 variants were scored at 0 and 1 (classed as nega-
tive in our scoring system), and only one sample had a score 
Figure 1. PASD1 was found to be expressed in a number of human cancer cell lines. PASD1 expression was identified in K562, THIEL, HeLa, SW480, 
and sk-mel-28 cells; however, it was not found in the ovcar3, skov3, and a2780 ovarian cancer cell lines. Cells only and isotype controls were used 
as negative controls while no primary was used to determine background staining. actin was used as a positive control. red arrows indicate the brown 
deposition that identifies the subcellular localization of the immunolabeled target protein.
of 2 (scores of 2–4 were classed as positive). There was very 
little background staining for both of the antigens, although 
one core of NAT scored positively for PASD1b. We found 
no expression of PASD1b in endometrial tissues (Table 2C). 
In contrast, CA125 expression was identified in 12/165 stage I, 
1/15 stage II (P =  0.576), 0/3 stage IIIc, and 0/4 stage  IV 
tumors. These frequencies of expression were not significant 
when compared to the normal tissue (P = 0.536, 0.576, 1, and 
1, respectively).
The single core of malignant melanoma skin tissue on 
each TMA was positive following immunolabeling with 
either of the PASD1 antibodies, providing a positive control 
for PASD1 staining.
Discussion
The aim of our study was to investigate the expression of PASD1 
protein expression in early-stage ovarian cancer through the 
PASD1 expression in ovarian cancer 
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Figure 2. expression of PasD1 in ovarian cancer Tmas. images show the PasD1 staining of representative ovarian cancer samples at various stages of 
the disease. Each sample is identified by a unique sample identifier, ie, OT1, OT2, OT3, etc, followed by disease stage as indicated by a roman numeral 
and an alphabetical letter, ie, ia, ib, etc. PasD1 expression was predominantly absent from the ovarian cancer tissues tested. Ca125 was used as a 
comparator as it is the industry standard for the confirmation of a diagnosis of ovarian cancer. Cells only and isotype controls were used as negative 
controls and actin as a positive control. The single melanoma (skin tumor) sample on each Tma was used as a positive control for immunolabeling with 
the PasD1 antibodies. skin tumor samples expressed higher levels of actin, Ca125, and PasD1 but did not immunolabel when incubated with isotype 
control antibody. naTs and normal ovarian tissues (nTs) were also tested and were predominantly negative except for actin expression.
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use of TMAs. To optimize staining with the PASD1a and 
PASD1b antibodies, we identified PASD1 protein expres-
sion in leukemia (K562), multiple myeloma (THIEL), cervical 
cancer (HeLa), colorectal cancer (SW480), and a melanoma 
cell line (SK-Mel-28). We confirmed the previously pub-
lished data,10,11,13 including the study by Liggins et al,10 who 
had found PASD1 expression in K562, HeLa, SW480, and 
G361 (melanoma) cell lines. The staining we observed was 
cytoplasmic and nuclear as described previously.16 However, 
PASD1 expression was not detected in the ovarian cancer cell 
lines: Skov3, Ovcar3, and A2780. Liggins et al10 discovered 
some transcript expression of PASD1 in three ovarian cancer 
tumor tissues; however, this was quite weak when compared 
to the other solid tumor tissues tested such as the kidney and 
prostate. We did see some staining that achieved a score of 2 
for PASD1b (1/8) with NAT but there is some evidence that 
PASD1 mRNA may be present in histologically normal tissues 
signaling the potential of the cells to become cancerous.10,24
The expression of a number of other CTAs have been 
examined in ovarian cancer (summarized in Table 1), and some 
of these antigens have shown a frequency of expression, which 
make them promising targets for immunotherapy clinical tri-
als. These include Spag9 whose mRNA and protein expression 
was detected in 18/20 tissue samples, while Spag9 transcripts 
were detected in 15/17 and protein expression observed in 
11/19 serous ovarian cancer samples.25 OY-TES-1 was found 
to be predominantly expressed in papillary serous patient sam-
ples (43/100) along with 26 other patient samples in the cohort 
analyzed.26 NY-ESO-1 and/or LAGE-1 mRNA transcripts 
were found in 42/107 EOC samples, most of these tran-
scripts were detected in samples from patients with stage IIIc 
disease.27 In papillary serous or mixed ovarian cancer tumors, 
Sperm protein 17 (Sp17) transcripts were detected by reverse 
transcription-polymerase chain reaction (RT-PCR) in 15/18 
samples and by Northern blot in 17/25 samples.28 Of note, 
synovial sarcoma X 4 (SSX4) was detected in 19/120 EOC 
mostly stage IIIc patient samples,29 while A-kinase anchoring 
protein 3 (AKAP3) mRNA expression was found in a total 
of 43/74 ovarian cancer specimens, including 36/43 serous 
samples most of which were stage IIIc.30 In contrast, when 
we examined ovarian cancer tissue for PASD1 expression, we 
found infrequent expression that may reflect the predomi-
nantly early-stage disease samples we examined.
Although PASD1 does show some expression in some 
solid cancer samples and cell lines, expression has still pre-
dominately been identified in hematological cancers such as 
leukemia and lymphomas.10,11 PASD1 is located on Xq28, 
and mutations in the q28 region have been linked with 
increased risk of lymphoma and leukemia,31 indicating a 
potentially important role for PASD1 as a target for immu-
notherapy for blood cancers. In addition, PASD1 expression 
has not been found in any of the 78 basal cell carcinoma 
samples and 15 normal skin samples using semiquantitative 
RT-PCR.15
CA125 was expressed more frequently than PASD1 in our 
study of ovarian cancer samples; however, CA125 has been proven 
to have low specificity and sensitivity, and inconsistent expression 
patterns among different patients. In our study, we found CA125 
expression in normal endometrial tissue and tissues with inflam-
mation and reports of expression in endometrial cell growth and 
deciduation have been published previously.32 CA125 is mainly 
used as a marker to detect disease relapse and for monitoring 
treatment efficacy rather than primary ovarian cancer;33 how-
ever, it may be more effective as a marker for predicting advanced 
stage disease.34 CA125 has also been found in endometrial can-
cer where raised CA125 correlated with worse overall disease-
specific survival (66.1 vs 87.8 months, P = 0.021).35
A new PASD1 immune response was described in a mel-
anoma patient who achieved complete remission after irradia-
tion as part of an abscopal effect.36 Similarly, we found PASD1 
expression in the skin tumor sample on each ovarian cancer 
array providing a positive control, indicating that the PASD1 
antibodies were working on the paraffin-embedded tissues 
analyzed in this study. Previously, PASD1 expression has been 
demonstrated in more advanced tumor stages, in some solid 
tumor cell lines Hn5 (head and neck),11 SW480 (colorectal 
adenocarcinoma),10 and H1299 (lung cancer).37 Twenty-five of 
68 solid tumor tissues expressed PASD1.10 PASD1 has also 
been found to be expressed in 22/25 cell lines derived from 
21 B- and four T-cell malignancies by RT-PCR.38 We now 
add to this knowledge showing that PASD1 is not expressed 
in ovarian cancer, particularly at the early stages of the 
disease. This adds to a growing list of solid tumors (78 basal 
cell carcinomas),15 which do not appear to express PASD1 at 
notable levels. We also found that PASD1 was not expressed 
in healthy or inflamed endometrial tissues indicating a high 
level of specificity of expression, consistent with its description 
as a CTA. Other groups have found PASD1 to be expressed 
in the nuclei of a subpopulation of spermatogonia near the 
basal membrane in the testicular tubules.16 A feature typical of 
CTAs with the most restricted expression in healthy tissues.
We believe that it is important to publish well-controlled 
null data39 so that other groups do not need to repeat these 
studies and so the true expression of antigens like PASD1 
can become clear to the research community. Our search for 
a CTA that is expressed in ovarian tissues but not healthy 
tissues continues.
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